Bausch Settles Pay for Delay Claims with $300 Million Charge
“Court filings show that Canada-headquartered Bausch Health TSX. BHC has agreed to pay $300 million to settle an antitrust suit related to diabetes med Glumetza. The class action suit accused the firm of keeping a monopoly on the therapy by paying off competitors, thereby enabling an eight fold price,” reports The Pharma Letter in their blog.
“First sold by Assertio Therapeutics Nasdaq. ASRT, Glumetza is an extended-release formulation of the common diabetes therapy. Bausch, which was formerly known as Valeant Pharmaceuticals, picked up the treatment subsequently. The antitrust case was initiated in 2019. The legal arguments center around the role.”
